메뉴 건너뛰기




Volumn 4, Issue 2, 2013, Pages 133-145

Small molecule sequential dual-targeting theragnostic strategy (SMSDTTS): From preclinical experiments towards possible clinical anticancer applications

Author keywords

Combretastatin A4 phosphate; Hypericin; Necrosis avid contrast agent; Small molecule sequential dual targeting theragnostic strategy; SMSDTTS; Vascular disrupting agent

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIS GADOLINIUM PENTATE BENZYLIDENE BIS; BIS GADOLINIUM PENTATE MESOPORPHYRIN; BIS GADOLINIUM PENTATE PAMOIC ACID; COMBRETASTATIN A4 PHOSPHATE; CYTOTOXIC AGENT; GADOLINIUM PENTETATE; GADOPHRIN 2; HYPERICIN I 131; IODINE 131; MANGANESE TETRAPHENYLPORPHYRIN; PORPHYRIN DERIVATIVE; PYROPHOSPHATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

EID: 84882963376     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5635     Document Type: Review
Times cited : (19)

References (105)
  • 2
    • 68849085858 scopus 로고    scopus 로고
    • Models for prevention and treatment of cancer: problems vs promises
    • Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009; 78: 1083-94.
    • (2009) Biochem Pharmacol. , vol.78 , pp. 1083-1094
    • Aggarwal, B.B.1    Danda, D.2    Gupta, S.3    Gehlot, P.4
  • 4
    • 0026067043 scopus 로고
    • Cancer metastasis
    • Fidler IJ. Cancer metastasis. Br Med Bull. 1991; 47: 157-77.
    • (1991) Br Med Bull. , vol.47 , pp. 157-177
    • Fidler, I.J.1
  • 5
    • 33644846740 scopus 로고    scopus 로고
    • CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape
    • Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol. 2006; 176: 3374-82.
    • (2006) J Immunol. , vol.176 , pp. 3374-3382
    • Liu, K.1    Caldwell, S.A.2    Greeneltch, K.M.3    Yang, D.4    Abrams, S.I.5
  • 7
    • 79960836519 scopus 로고    scopus 로고
    • MRI & MRS assessment of the role of the tumour microenvironment in response to therapy
    • Bell LK, Ainsworth NL, Lee SH, Griffiths JR. MRI & MRS assessment of the role of the tumour microenvironment in response to therapy. NMR Biomed. 2011; 24: 612-35.
    • (2011) NMR Biomed. , vol.24 , pp. 612-635
    • Bell, L.K.1    Ainsworth, N.L.2    Lee, S.H.3    Griffiths, J.R.4
  • 9
    • 0036381439 scopus 로고    scopus 로고
    • Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin
    • Khawli LA, Mizokami MM, Sharifi J, Hu P, Epstein AL. Pharmacokinetic characteristics and biodistribution of radioiodinated chimeric TNT-1, -2, and -3 monoclonal antibodies after chemical modification with biotin. Cancer Biother Radiopharm. 2002; 17: 359-70.
    • (2002) Cancer Biother Radiopharm. , vol.17 , pp. 359-370
    • Khawli, L.A.1    Mizokami, M.M.2    Sharifi, J.3    Hu, P.4    Epstein, A.L.5
  • 11
    • 84860390456 scopus 로고    scopus 로고
    • A Dual-targeting Anticancer Approach: Soil and Seed Principle
    • Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, et al. A Dual-targeting Anticancer Approach: Soil and Seed Principle. Radiology. 2011; 260:799-807.
    • (2011) Radiology. , vol.260 , pp. 799-807
    • Li, J.1    Sun, Z.2    Zhang, J.3    Shao, H.4    Miranda Cona, M.5
  • 13
    • 33644832204 scopus 로고    scopus 로고
    • Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin
    • Papadimitriou D, Kottou S, Oros L, Ilias I, Molfetas M, et al. Differentiated thyroid cancer: comparison of therapeutic iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin. Annals of Nuclear Medicine. 2006; 20: 63-67.
    • (2006) Annals of Nuclear Medicine. , vol.20 , pp. 63-67
    • Papadimitriou, D.1    Kottou, S.2    Oros, L.3    Ilias, I.4    Molfetas, M.5
  • 14
    • 0032053823 scopus 로고    scopus 로고
    • The unique physiology of solid tumors: opportunities (and problems) for cancer therapy
    • Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
    • (1998) Cancer Res , vol.58 , pp. 1408-1416
    • Brown, J.M.1    Giaccia, A.J.2
  • 15
    • 0036488496 scopus 로고    scopus 로고
    • Specialization of tumour vasculature
    • Ruoslahti E. Specialization of tumour vasculature. Nature Reviews Cancer. 2012; 2: 83-90.
    • (2012) Nature Reviews Cancer. , vol.2 , pp. 83-90
    • Ruoslahti, E.1
  • 16
    • 0026011103 scopus 로고
    • Angiogenic attack as a therapeutic strategy for cancer
    • Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol. 1991; 20: 103-12.
    • (1991) Radiother Oncol. , vol.20 , pp. 103-112
    • Denekamp, J.1    Hill, S.2
  • 17
    • 33751583518 scopus 로고    scopus 로고
    • Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery
    • Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery. Nat Clin Pract Oncol. 2006; 3: 682-92.
    • (2006) Nat Clin Pract Oncol. , vol.3 , pp. 682-692
    • Cooney, M.M.1    van Heeckeren, W.2    Bhakta, S.3    Ortiz, J.4    Remick, S.C.5
  • 18
    • 0032514402 scopus 로고    scopus 로고
    • Vascular targeting as a strategy for cancer therapy
    • Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N Engl J Med. 1998; 339: 472-4.
    • (1998) N Engl J Med. , vol.339 , pp. 472-474
    • Schnitzer, J.E.1
  • 19
    • 0032535999 scopus 로고    scopus 로고
    • Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    • Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279: 377-80.
    • (1998) Science. , vol.279 , pp. 377-380
    • Arap, W.1    Pasqualini, R.2    Ruoslahti, E.3
  • 20
    • 57749202046 scopus 로고    scopus 로고
    • Vascular targeted therapies in oncology
    • Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res. 2009; 335: 241-8.
    • (2009) Cell Tissue Res. , vol.335 , pp. 241-248
    • Siemann, D.W.1    Horsman, M.R.2
  • 22
    • 16844367677 scopus 로고    scopus 로고
    • Novel vascular targeting/ disrupting agents: combretastatin A4 phosphate and related compounds
    • Cooney MM, Ortiz J, Bukowski RM, Remick SC. Novel vascular targeting/ disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep. 2005; 7: 90-5.
    • (2005) Curr Oncol Rep. , vol.7 , pp. 90-95
    • Cooney, M.M.1    Ortiz, J.2    Bukowski, R.M.3    Remick, S.C.4
  • 23
    • 1642352048 scopus 로고    scopus 로고
    • Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
    • Ching LM, Zwain S, Baguley BC. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer. 2004; 90: 906-10.
    • (2004) Br J Cancer. , vol.90 , pp. 906-910
    • Ching, L.M.1    Zwain, S.2    Baguley, B.C.3
  • 24
    • 33847247311 scopus 로고    scopus 로고
    • Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome
    • Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, et al. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia. 2007; 9:128-35.
    • (2007) Neoplasia. , vol.9 , pp. 128-135
    • Seshadri, M.1    Spernyak, J.A.2    Maiery, P.G.3    Cheney, R.T.4    Mazurchuk, R.5
  • 25
    • 33646342514 scopus 로고    scopus 로고
    • Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast- enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis
    • McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast- enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia. 2006; 8: 199-206.
    • (2006) Neoplasia. , vol.8 , pp. 199-206
    • McPhail, L.D.1    McIntyre, D.J.2    Ludwig, C.3    Kestell, P.4    Griffiths, J.R.5
  • 26
    • 0033565644 scopus 로고    scopus 로고
    • Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
    • Ching LM, Goldsmith D, Joseph WR, Körner H, Sedgwick JD, et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 1999; 59: 3304-7.
    • (1999) Cancer Res. , vol.59 , pp. 3304-3307
    • Ching, L.M.1    Goldsmith, D.2    Joseph, W.R.3    Körner, H.4    Sedgwick, J.D.5
  • 27
    • 84882991992 scopus 로고    scopus 로고
    • The Role of Modern Medical Imaging in Evaluation of Tumor Response to Vascular Targeting Therapy
    • ISBN 978-960-474-278-3
    • Wang H, Cona MM, Li J, Feng Y, Chen F, et al. The Role of Modern Medical Imaging in Evaluation of Tumor Response to Vascular Targeting Therapy. Recent Researches in Modern Medicine. 2009; ISBN: 978-960-474-278-3.
    • (2009) Recent Researches in Modern Medicine.
    • Wang, H.1    Cona, M.M.2    Li, J.3    Feng, Y.4    Chen, F.5
  • 28
    • 29344471072 scopus 로고    scopus 로고
    • Understanding microtubule dynamics for improved cancer therapy
    • Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. 2005; 62: 3039-56.
    • (2005) Cell Mol Life Sci. , vol.62 , pp. 3039-3056
    • Honore, S.1    Pasquier, E.2    Braguer, D.3
  • 29
    • 78649833819 scopus 로고    scopus 로고
    • The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
    • Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev. 2010; 37: 63-74.
    • (2010) Cancer Treat Rev. , vol.37 , pp. 63-74
    • Siemann, D.W.1
  • 30
    • 79953741443 scopus 로고    scopus 로고
    • A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment
    • Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb). 2011; 3: 375-87.
    • (2011) Integr Biol (Camb). , vol.3 , pp. 375-387
    • Mason, R.P.1    Zhao, D.2    Liu, L.3    Trawick, M.L.4    Pinney, K.G.5
  • 32
    • 33847048710 scopus 로고    scopus 로고
    • Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications
    • Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol.2007; 170: 1-15.
    • (2007) Am J Pathol. , vol.170 , pp. 1-15
    • Dome, B.1    Hendrix, M.J.2    Paku, S.3    Tovari, J.4    Timar, J.5
  • 33
    • 64249135764 scopus 로고    scopus 로고
    • Novel agents on the horizon for cancer therapy
    • Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009; 59: 111-37.
    • (2009) CA Cancer J Clin. , vol.59 , pp. 111-137
    • Ma, W.W.1    Adjei, A.A.2
  • 34
    • 79953648492 scopus 로고    scopus 로고
    • Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
    • Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011; 22: 2036-41.
    • (2011) Ann Oncol. , vol.22 , pp. 2036-2041
    • Zweifel, M.1    Jayson, G.C.2    Reed, N.S.3    Osborne, R.4    Hassan, B.5
  • 35
    • 0042386700 scopus 로고    scopus 로고
    • Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results
    • Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003; 21: 2815-22.
    • (2003) J Clin Oncol. , vol.21 , pp. 2815-2822
    • Rustin, G.J.1    Galbraith, S.M.2    Anderson, H.3    Stratford, M.4    Folkes, L.K.5
  • 37
    • 0035417875 scopus 로고    scopus 로고
    • Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability
    • Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001; 61: 6413-22.
    • (2001) Cancer Res. , vol.61 , pp. 6413-6422
    • Tozer, G.M.1    Prise, V.E.2    Wilson, J.3    Cemazar, M.4    Shan, S.5
  • 38
    • 66649086232 scopus 로고    scopus 로고
    • Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses
    • Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, et al. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res. 2009; 15: 3781-90.
    • (2009) Clin Cancer Res. , vol.15 , pp. 3781-3790
    • Tozer, G.M.1    Prise, V.E.2    Lewis, G.3    Xie, S.4    Wilson, I.5
  • 39
    • 34247173906 scopus 로고    scopus 로고
    • Characterizing the tumor response to treatment with combretastatin A4 phosphate
    • Salmon BA, Siemann DW. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys. 2007; 68: 211-7.
    • (2007) Int J Radiat Oncol Biol Phys. , vol.68 , pp. 211-217
    • Salmon, B.A.1    Siemann, D.W.2
  • 40
    • 77951667223 scopus 로고    scopus 로고
    • A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
    • Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer. 2010; 102: 1355-60.
    • (2010) Br J Cancer. , vol.102 , pp. 1355-1360
    • Rustin, G.J.1    Shreeves, G.2    Nathan, P.D.3    Gaya, A.4    Ganesan, T.S.5
  • 41
    • 67249095624 scopus 로고    scopus 로고
    • Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors
    • Mitrus I, Sochanik A, Cichon T, Szala S. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim Pol. 2009; 56: 161-5.
    • (2009) Acta Biochim Pol. , vol.56 , pp. 161-165
    • Mitrus, I.1    Sochanik, A.2    Cichon, T.3    Szala, S.4
  • 43
    • 42449123761 scopus 로고    scopus 로고
    • Expansion and evolution of cell death programmes
    • Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol. 2008; 9: 378-90.
    • (2008) Nat Rev Mol Cell Biol. , vol.9 , pp. 378-390
    • Degterev, A.1    Yuan, J.2
  • 44
    • 0031719489 scopus 로고    scopus 로고
    • Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells
    • Korostoff J, Wang JF, Kieba I, Miller M, Shenker BJ, et al. Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells. Infect Immun. 1998; 66: 4474-83.
    • (1998) Infect Immun. , vol.66 , pp. 4474-4483
    • Korostoff, J.1    Wang, J.F.2    Kieba, I.3    Miller, M.4    Shenker, B.J.5
  • 45
    • 77955133412 scopus 로고    scopus 로고
    • Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA
    • Dasari M, Lee S, Sy J, Kim D, Brown M, et al. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Org Lett. 2010; 12: 3300-3.
    • (2010) Org Lett. , vol.12 , pp. 3300-3303
    • Dasari, M.1    Lee, S.2    Sy, J.3    Kim, D.4    Brown, M.5
  • 47
    • 22844434974 scopus 로고    scopus 로고
    • Necrosis avid contrast agents: functional similarity versus structural diversity
    • Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol. 2005; 40: 526-35.
    • (2005) Invest Radiol. , vol.40 , pp. 526-535
    • Ni, Y.1    Bormans, G.2    Chen, F.3    Verbruggen, A.4    Marchal, G.5
  • 48
    • 0029347647 scopus 로고
    • Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings
    • Ni Y, Marchal G, Yu J, Lukito G, Petre C, et al. Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings. Acad Radiol.1995; 2: 687-99.
    • (1995) Acad Radiol. , vol.2 , pp. 687-699
    • Ni, Y.1    Marchal, G.2    Yu, J.3    Lukito, G.4    Petre, C.5
  • 49
    • 0026784206 scopus 로고
    • Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer
    • Ni Y, Marchal G, van Damme B, van Hecke P, Michiels J, et al. Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer. Invest Radiol. 1992; 27: 689-97.
    • (1992) Invest Radiol. , vol.27 , pp. 689-697
    • Ni, Y.1    Marchal, G.2    van Damme, B.3    van Hecke, P.4    Michiels, J.5
  • 50
    • 0037655063 scopus 로고    scopus 로고
    • Non-invasive in vivo imaging of myocardial apoptosis and necrosis
    • Flotats A, Carrio I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging. 2003; 30: 615-30.
    • (2003) Eur J Nucl Med Mol Imaging. , vol.30 , pp. 615-630
    • Flotats, A.1    Carrio, I.2
  • 51
    • 0031451125 scopus 로고    scopus 로고
    • Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis
    • Ni Y, Petre C, Miao Y, Yu J, Cresens E, et al. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol. 1997; 32: 770-779.
    • (1997) Invest Radiol. , vol.32 , pp. 770-779
    • Ni, Y.1    Petre, C.2    Miao, Y.3    Yu, J.4    Cresens, E.5
  • 52
    • 0035128069 scopus 로고    scopus 로고
    • MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction
    • Ni Y, Adzamli K, Miao Y, Cresens E, Yu J, et al. MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction. Invest Radiol. 2001; 36: 97-103.
    • (2001) Invest Radiol. , vol.36 , pp. 97-103
    • Ni, Y.1    Adzamli, K.2    Miao, Y.3    Cresens, E.4    Yu, J.5
  • 53
    • 45949097340 scopus 로고    scopus 로고
    • Metalloporphyrins and Functional Analogues as MRI Contrast Agents
    • Ni Y. Metalloporphyrins and Functional Analogues as MRI Contrast Agents. Current Medical Imaging Reviews. 2008; 4: 96-112.
    • (2008) Current Medical Imaging Reviews. , vol.4 , pp. 96-112
    • Ni, Y.1
  • 54
    • 66149142228 scopus 로고    scopus 로고
    • Vessel growth and function: depiction with contrast-enhanced MR imaging
    • Oostendorp M, Post MJ, Backes WH. Vessel growth and function: depiction with contrast-enhanced MR imaging. Radiology. 2009; 251: 317-35.
    • (2009) Radiology. , vol.251 , pp. 317-335
    • Oostendorp, M.1    Post, M.J.2    Backes, W.H.3
  • 55
    • 0026595006 scopus 로고
    • Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging
    • Weissleder R, Lee A, Khaw B, Shen T, Brady T. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology.1992; 182: 381-5.
    • (1992) Radiology. , vol.182 , pp. 381-385
    • Weissleder, R.1    Lee, A.2    Khaw, B.3    Shen, T.4    Brady, T.5
  • 56
    • 0017811473 scopus 로고
    • The prognostic implications of acute myocardial infarct scintigraphy with 99mTc-pyrophosphate
    • Holman BL, Chisholm RJ, Braunwald E. The prognostic implications of acute myocardial infarct scintigraphy with 99mTc-pyrophosphate. Circulation. 1978; 57: 320-6.
    • (1978) Circulation. , vol.57 , pp. 320-326
    • Holman, B.L.1    Chisholm, R.J.2    Braunwald, E.3
  • 57
    • 0016431601 scopus 로고
    • Technetium-99m-pyrophosphate: studies in vivo and in vitro
    • Kaye M, Silverton S, Rosenthall L. Technetium-99m-pyrophosphate: studies in vivo and in vitro. J Nucl Med.1975; 16: 40-5.
    • (1975) J Nucl Med. , vol.16 , pp. 40-45
    • Kaye, M.1    Silverton, S.2    Rosenthall, L.3
  • 58
    • 33646396784 scopus 로고    scopus 로고
    • First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent
    • Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging. 2006; 33: 595-601.
    • (2006) Eur J Nucl Med Mol Imaging. , vol.33 , pp. 595-601
    • Ni, Y.1    Huyghe, D.2    Verbeke, K.3    de Witte, P.A.4    Nuyts, J.5
  • 60
    • 77649229910 scopus 로고    scopus 로고
    • Hypericins as Potential Leads for New Therapeutics
    • Karioti A, Bilia AR. Hypericins as Potential Leads for New Therapeutics. Int J Mol Sci. 2010; 11: 562-594.
    • (2010) Int J Mol Sci. , vol.11 , pp. 562-594
    • Karioti, A.1    Bilia, A.R.2
  • 61
    • 0035315837 scopus 로고    scopus 로고
    • Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy
    • Chen B, Zupko I, de Witte PA. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int J Oncol. 2001; 18: 737-42.
    • (2001) Int J Oncol. , vol.18 , pp. 737-742
    • Chen, B.1    Zupko, I.2    de Witte, P.A.3
  • 62
    • 0036878574 scopus 로고    scopus 로고
    • Antivascular tumor eradication by hypericin-mediated photodynamic therapy
    • Chen B, Roskams T, de Witte PA. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol. 2002; 76: 509-13.
    • (2002) Photochem Photobiol. , vol.76 , pp. 509-513
    • Chen, B.1    Roskams, T.2    de Witte, P.A.3
  • 64
    • 0030922812 scopus 로고    scopus 로고
    • Binding, uptake, and transport of hypericin by Caco-2 cell monolayers
    • Sattler S, Schaefer U, Schneider W. Hoelzl J, Lehr CM. Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. J Pharm Sci.1997; 86: 1120-6.
    • (1997) J Pharm Sci. , vol.86 , pp. 1120-1126
    • Sattler, S.1    Schaefer, U.2    Schneider, W.3    Hoelzl, J.4    Lehr, C.M.5
  • 65
    • 0026873378 scopus 로고
    • Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells
    • Thomas C, Pardini RS. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem Photobiol. 1992; 55: 831-7.
    • (1992) Photochem Photobiol. , vol.55 , pp. 831-837
    • Thomas, C.1    Pardini, R.S.2
  • 67
    • 0033094534 scopus 로고    scopus 로고
    • Subcellular distributions and excited-state processes of hypericin in neurons
    • English DS, Doyle RT, Petrich JW, Haydon PG. Subcellular distributions and excited-state processes of hypericin in neurons. Photochem Photobiol. 1999; 69: 301-5.
    • (1999) Photochem Photobiol. , vol.69 , pp. 301-305
    • English, D.S.1    Doyle, R.T.2    Petrich, J.W.3    Haydon, P.G.4
  • 69
    • 34547538159 scopus 로고    scopus 로고
    • Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor
    • Fonge H, Van de Putte M, Huyghe D, Bormans G, Ni Y, et al. Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media Mol Imaging.2007; 2: 113-9.
    • (2007) Contrast Media Mol Imaging. , vol.2 , pp. 113-119
    • Fonge, H.1    Van de Putte, M.2    Huyghe, D.3    Bormans, G.4    Ni, Y.5
  • 70
    • 38649131018 scopus 로고    scopus 로고
    • Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT
    • Fonge H, Vunckx K, Wang H, Feng Y, Mortelmans L, et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J. 2008; 29: 260-9.
    • (2008) Eur Heart J. , vol.29 , pp. 260-269
    • Fonge, H.1    Vunckx, K.2    Wang, H.3    Feng, Y.4    Mortelmans, L.5
  • 71
    • 43849086304 scopus 로고    scopus 로고
    • Exploration of the mechanism underlying the tumor necrosis avidity of hypericin
    • Van de Putte M, Ni Y, De Witte PA. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep. 2008; 19: 921-6.
    • (2008) Oncol Rep. , vol.19 , pp. 921-926
    • Van de Putte, M.1    Ni, Y.2    De Witte, P.A.3
  • 72
    • 43849086838 scopus 로고    scopus 로고
    • Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model
    • Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep. 2008; 19: 927-32.
    • (2008) Oncol Rep. , vol.19 , pp. 927-932
    • Van de Putte, M.1    Wang, H.2    Chen, F.3    De Witte, P.A.4    Ni, Y.5
  • 73
    • 36749065586 scopus 로고    scopus 로고
    • Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model
    • Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol. 2008; 15: 107-13.
    • (2008) Acad Radiol. , vol.15 , pp. 107-113
    • Van de Putte, M.1    Wang, H.2    Chen, F.3    de Witte, P.A.4    Ni, Y.5
  • 75
    • 0023784524 scopus 로고
    • A novel method for the detection of necrotic lesions in human cancers
    • Epstein AL, Chen FM, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res.1988; 48: 5842-8.
    • (1988) Cancer Res. , vol.48 , pp. 5842-5848
    • Epstein, A.L.1    Chen, F.M.2    Taylor, C.R.3
  • 76
    • 84867865246 scopus 로고    scopus 로고
    • Continuing pursuit for ideal systemic anticancer radiotherapeutics
    • Cona MM, Wang H, Li J, Feng Y, Chen F, et al. Continuing pursuit for ideal systemic anticancer radiotherapeutics. Invest New Drugs. 2012; 30:2050-65.
    • (2012) Invest New Drugs. , vol.30 , pp. 2050-2065
    • Cona, M.M.1    Wang, H.2    Li, J.3    Feng, Y.4    Chen, F.5
  • 77
    • 0026683490 scopus 로고
    • Radioimmunotherapy of cancer: arming the missiles
    • Goldenberg DM, Griffiths GL. Radioimmunotherapy of cancer: arming the missiles. J Nucl Med. 1992; 33: 1110-2.
    • (1992) J Nucl Med. , vol.33 , pp. 1110-1112
    • Goldenberg, D.M.1    Griffiths, G.L.2
  • 78
    • 15244351004 scopus 로고    scopus 로고
    • Overview of monoclonal antibodies in cancer therapy: present and promise
    • Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005; 54: 11-29.
    • (2005) Crit Rev Oncol Hematol. , vol.54 , pp. 11-29
    • Stern, M.1    Herrmann, R.2
  • 79
    • 84862781827 scopus 로고    scopus 로고
    • Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential
    • Van de Putte M, Marysael T, Fonge H, Roskams T, Cona MM, et al. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer. 2011; 131: 129-137
    • (2011) Int J Cancer. , vol.131 , pp. 129-137
    • Van de Putte, M.1    Marysael, T.2    Fonge, H.3    Roskams, T.4    Cona, M.M.5
  • 80
    • 17944383454 scopus 로고    scopus 로고
    • Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging
    • Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, et al. Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol. 2001; 11: 876-83.
    • (2001) Eur Radiol. , vol.11 , pp. 876-883
    • Ni, Y.1    Pislaru, C.2    Bosmans, H.3    Pislaru, S.4    Miao, Y.5
  • 81
    • 33750823665 scopus 로고    scopus 로고
    • Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
    • Ginj M, Zhang H, Waser B, Cescato R, Wild D, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006; 103: 16436-41.
    • (2006) Proc Natl Acad Sci U S A. , vol.103 , pp. 16436-16441
    • Ginj, M.1    Zhang, H.2    Waser, B.3    Cescato, R.4    Wild, D.5
  • 82
    • 84883006320 scopus 로고    scopus 로고
    • Systemic Sequential Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin: Synergistic Targeted Anticancer Effect with Prolonged Survival in a Murine Model of Subcutaneous Tumor Xenografts
    • (In press)
    • Li J, Cona MM, Chen F, Zhou L, Nuyts J, et al. Systemic Sequential Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin: Synergistic Targeted Anticancer Effect with Prolonged Survival in a Murine Model of Subcutaneous Tumor Xenografts. Theranostics. (In press).
    • Theranostics
    • Li, J.1    Cona, M.M.2    Chen, F.3    Zhou, L.4    Nuyts, J.5
  • 83
    • 78650317418 scopus 로고    scopus 로고
    • Nanoparticle-assisted combination therapies for effective cancer treatment
    • Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery. 2010; 1: 323-334.
    • (2010) Therapeutic Delivery. , vol.1 , pp. 323-334
    • Hu, C.M.1    Aryal, S.2    Zhang, L.3
  • 84
    • 33645051467 scopus 로고    scopus 로고
    • Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC
    • Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006; 11: 274-84.
    • (2006) Oncologist. , vol.11 , pp. 274-284
    • Maione, P.1    Gridelli, C.2    Troiani, T.3    Ciardiello, F.4
  • 85
    • 80051769183 scopus 로고    scopus 로고
    • Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer
    • Wang H, Marchal G, Ni Y. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol. 2011; 3: 1-16.
    • (2011) World J Radiol. , vol.3 , pp. 1-16
    • Wang, H.1    Marchal, G.2    Ni, Y.3
  • 86
    • 77956301345 scopus 로고    scopus 로고
    • Combretastatin A4 phosphate: a novel vascular disrupting agent
    • Nagaiah G, Remick SC. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol. 2010; 6: 1219-28.
    • (2010) Future Oncol. , vol.6 , pp. 1219-1228
    • Nagaiah, G.1    Remick, S.C.2
  • 87
    • 49049086508 scopus 로고    scopus 로고
    • Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503)
    • Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008; 28: 2027-31.
    • (2008) Anticancer Res. , vol.28 , pp. 2027-2031
    • Siemann, D.W.1    Shi, W.2
  • 88
    • 84855176809 scopus 로고    scopus 로고
    • Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck
    • Ng QS, Mandeville H, Goh V, Alonzi R, Milner J, et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Ann Oncol. 2005; 23: 231-7.
    • (2005) Ann Oncol. , vol.23 , pp. 231-237
    • Ng, Q.S.1    Mandeville, H.2    Goh, V.3    Alonzi, R.4    Milner, J.5
  • 89
    • 80054760369 scopus 로고    scopus 로고
    • Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors
    • Marysael T, Ni Y, Lerut E, de Witte P. Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors. J Cancer Res Clin Oncol. 2011;137:1619-27.
    • (2011) J Cancer Res Clin Oncol. , vol.137 , pp. 1619-27
    • Marysael, T.1    Ni, Y.2    Lerut, E.3    de Witte, P.4
  • 90
    • 84870478186 scopus 로고    scopus 로고
    • Exploring Diagnostic and Therapeutic Potentials of Radioiodinated Hypericin in Animal Models of Pathologies
    • Li J, Cona MM, Chen F, Zhou L, Nuyts J, et al. Exploring Diagnostic and Therapeutic Potentials of Radioiodinated Hypericin in Animal Models of Pathologies. Theranostics. 2012; 2: 1010-1019.
    • (2012) Theranostics. , vol.2 , pp. 1010-101019
    • Li, J.1    Cona, M.M.2    Chen, F.3    Zhou, L.4    Nuyts, J.5
  • 91
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
    • (2005) Science. , vol.307 , pp. 58-62
    • Jain, R.K.1
  • 93
    • 0036760384 scopus 로고    scopus 로고
    • Chemo-radionuclide therapy for thyroid cancer: Initial experimental study with cultured cells
    • Misaki T, Iwata M, Iida Y, Kasagi K, Konishi J. Chemo-radionuclide therapy for thyroid cancer: Initial experimental study with cultured cells. Annals of Nuclear Medicine. 2002; 16: 403-408
    • (2002) Annals of Nuclear Medicine. , vol.16 , pp. 403-4408
    • Misaki, T.1    Iwata, M.2    Iida, Y.3    Kasagi, K.4    Konishi, J.5
  • 94
    • 84879926744 scopus 로고    scopus 로고
    • A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [Iodogen] dissolved in dimethyl sulfoxide [DMSO]
    • epub
    • Cona MM, Li J, Chen F, Feng Y, Alpizar Y, et al. A safety study on single intravenous dose of tetrachloro-diphenyl glycoluril [Iodogen] dissolved in dimethyl sulfoxide [DMSO]. XENOBIOTICA 2013; epub.
    • (2013) XENOBIOTICA
    • Cona, M.M.1    Li, J.2    Chen, F.3    Feng, Y.4    Alpizar, Y.5
  • 95
    • 84870510435 scopus 로고    scopus 로고
    • A Single-dose toxicity study in mice on non-radioactive iodinated hypericin for a targeted anticancer therapy
    • Li J. Cona MM, Feng Y, Chen F, Fu X, et al. A Single-dose toxicity study in mice on non-radioactive iodinated hypericin for a targeted anticancer therapy. Acta Pharmacologica Sinica. 2012; 33: 1549-1556.
    • (2012) Acta Pharmacologica Sinica. , vol.33 , pp. 1549-1556
    • Li, J.1    Cona, M.M.2    Feng, Y.3    Chen, F.4    Fu, X.5
  • 96
    • 34250377800 scopus 로고    scopus 로고
    • Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent
    • Fonge H, Jin L, Wang H, Ni Y, Bormans G, et al. Synthesis and preliminary evaluation of mono-[123I]iodohypericin monocarboxylic acid as a necrosis avid imaging agent. Bioorg Med Chem Lett. 2007; 17: 4001-5.
    • (2007) Bioorg Med Chem Lett. , vol.17 , pp. 4001-4005
    • Fonge, H.1    Jin, L.2    Wang, H.3    Ni, Y.4    Bormans, G.5
  • 97
    • 1942534033 scopus 로고    scopus 로고
    • Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin
    • Bormans G, Huyghe D, Christiaen A, Verbeke K, de Groot T, et al. Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin. J Label Compd Radiopharm. 2004; 47: 191-198.
    • (2004) J Label Compd Radiopharm. , vol.47 , pp. 191-198
    • Bormans, G.1    Huyghe, D.2    Christiaen, A.3    Verbeke, K.4    de Groot, T.5
  • 98
    • 84873902064 scopus 로고    scopus 로고
    • Transbilayer phospholipids molecular imaging
    • Belhocine TZ, Prato FS. Transbilayer phospholipids molecular imaging. EJNMMI Res. 2011; 1: 17.
    • (2011) EJNMMI Res. , vol.1 , pp. 17
    • Belhocine, T.Z.1    Prato, F.S.2
  • 99
    • 0031905742 scopus 로고    scopus 로고
    • Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay
    • Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, et al. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. J Nucl Med.1998; 39: 436-40.
    • (1998) J Nucl Med. , vol.39 , pp. 436-440
    • Watanabe, N.1    Yokoyama, K.2    Kinuya, S.3    Shuke, N.4    Shimizu, M.5
  • 101
    • 0026482808 scopus 로고
    • Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design
    • Narra VR, Howell RW, Harapanhalli RS, Sastry KS, Rao DV. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design. J Nucl Med. 1992; 33: 2196-201.
    • (1992) J Nucl Med. , vol.33 , pp. 2196-2201
    • Narra, V.R.1    Howell, R.W.2    Harapanhalli, R.S.3    Sastry, K.S.4    Rao, D.V.5
  • 102
    • 0037096814 scopus 로고    scopus 로고
    • A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer
    • Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002; 62: 3408-3416.
    • (2002) Cancer Res. , vol.62 , pp. 3408-3416
    • Dowlati, A.1    Robertson, K.2    Cooney, M.3
  • 103
    • 1642494772 scopus 로고    scopus 로고
    • Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer
    • Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004; 10: 96-100.
    • (2004) Clin Cancer Res. , vol.10 , pp. 96-100
    • Cooney, M.M.1    Radivoyevitch, T.2    Dowlati, A.3
  • 104
    • 84874715009 scopus 로고    scopus 로고
    • Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography and Histopathology
    • DOI: 10.1593/tlo.12367
    • Li J, Chen F, Feng Y, Miranda Cona M, Yu J, et al. Diverse Responses to Vascular Disrupting Agent Combretastatin A4 Phosphate: A Comparative Study in Rats with Hepatic and Subcutaneous Tumor Allografts Using MRI Biomarkers, Microangiography and Histopathology. Translational Oncology. DOI: 10.1593/tlo.12367.
    • Translational Oncology
    • Li, J.1    Chen, F.2    Feng, Y.3    Miranda Cona, M.4    Yu, J.5
  • 105
    • 84864015478 scopus 로고    scopus 로고
    • Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI
    • Chen F, Feng Y, Zheng K, De Keyzer F, Li J, et al. Enhanced Antitumor Efficacy of a Vascular Disrupting Agent Combined with an Antiangiogenic in a Rat Liver Tumor Model Evaluated by Multiparametric MRI. PLoS ONE. 2012; 7: e41140.
    • (2012) PLoS ONE. , vol.7
    • Chen, F.1    Feng, Y.2    Zheng, K.3    De Keyzer, F.4    Li, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.